1. USO DE CANABINOIDES COMO ADJUVANTE NO TRATAMENTO DA DOENÇA DE ALZHEIMER.
- Author
-
TEIXEIRA NOCETTI, CAROLINA and THEODORO RIBEIRO, LAIR GERALDO
- Abstract
Alzheimer's disease is a common cause of dementia in the elderly, and it is characterized by neuropsychiatric symptoms related to neuroanatomical and biochemical changes in the cerebral cortex. Drug treatment has little efficacy in more advanced stages of the disease, which leads to the search for adjuvant therapeutic resources. The endocannabinoid system has emerged with great scientific prominence as a therapeutic target in the treatment of Alzheimer's disease since its components are highly associated with the pathophysiology of the disease. This study aims to update the literature about scientific evidence regarding the therapeutic potential of the endocannabinoid system in the treatment of Alzheimer's disease. SciELO, PubMed/Medline, and Cochrane Library databases were consulted, using the following keywords: "Cannabis sativa"; "Cannabidiol"; "Endocannabinoid system"; "Cannabinoid"; "Alzheimer's disease". Eighty-seven (87) articles were considered, among literature reviews, experimental studies, and randomized double-blind and placebo-controlled clinical trials. Modulation of the endocannabinoid system showed high therapeutic potential, as it was able to slow the progression of Alzheimer's disease by reducing neuroinflammation, the accumulation of β-amyloid protein, and hyperphosphorylation of the tau protein. Such neuroprotective effects of cannabinoids favor neurogenesis, attenuation of neuropsychiatric symptoms, and improvement of memory, behavior and learning. [ABSTRACT FROM AUTHOR]
- Published
- 2020